The post-Covid FDA:
Regulating in a new era of medicine

June 30 | 1:00pm - 3:00pm EST

As the pandemic has upended the FDA, the agency has been tested like never before. Now that the influx of new EUA requests has tapered slightly, the FDA has a chance to look back on how it managed to keep pace and decide what parts of its pandemic-era processes are worth keeping.

Endpoints News editor Zachary Brennan will explore these questions with a key FDA official. And then he’ll moderate a panel of top biopharma analysts and drugmakers to talk about the new regulatory landscape.

sponsored by

Fireside Chat: Zachary Brennan and Theresa Mullin

Theresa Mullin

Theresa Mullin

Associate Director, Strategic Initiatives

Center for Drug Evaluation and Research (CDER), FDA

Zachary Brennan

Zachary Brennan

Senior Editor

Endpoints News

The post-Covid FDA

Covid-19 changed the R&D world. And it’s not going back to what it was before the pandemic. That’s particularly true at the FDA, which worked with developers to make it possible to continue trials when sites were shuttered around the world. We’ll explore what’s likely to stick now that the pandemic is winding down.

Mathias Hukkelhoven

Mathias Hukkelhoven

SVP, Global Regulatory & Safety Sciences

Bristol Myers Squibb

Nathan Cortez

Nathan Cortez

Professor of Law, Leadership & Latino Studies

SMU Dedman School of Law

Coleen Klasmeier

Coleen Klasmeier

Partner

Sidley

Colleen Herczak

Colleen Herczak presenting sponsor

Vice President, Quality

Grand River Aseptic Manufacturing

Zachary Brennan

Zachary Brennan moderator

Senior Editor

Endpoints News